Loading
Constellation Pharmaceuticals developed medicines for cancer that change which genes are switched on in cancer cells. MorphoSys bought it in 2021, and its drugs pelabresib and CPI-0209 (now tulmimetostat) went with it.
Constellation Pharmaceuticals was a clinical-stage company developing therapeutics that selectively modulate gene expression for patients with cancer (Third Rock Ventures). MorphoSys AG completed a cash tender offer at $34.00 a share on 15 July 2021, with a total equity value of about $1.7 billion, and Constellation became an indirect wholly owned subsidiary of MorphoSys. The MorphoSys release names Constellation's clinical-stage assets as pelabresib (CPI-0610) and CPI-0209, and also mentions two earlier programmes. Its common stock had traded on Nasdaq as CNST. MorphoSys is itself now part of Novartis.
Pelabresib is an experimental small-molecule drug from Novartis Pharmaceuticals in phase 3 trials, with its target not yet stated publicly.
Tulmimetostat is an experimental tablet that blocks the gene-silencing enzymes EZH1 and EZH2. Novartis gained it by buying MorphoSys in 2024 and is testing it in prostate cancer, lymphomas and other solid tumours.
Shares Pelabresib, MorphoSys (Novartis).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/